AstraZeneca, BMY To Target Disease Management And Primary Care Synergies With Amylin Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
In acquiring Amylin at a hefty premium, Bristol-Myers Squibb and its partner AstraZeneca are highly optimistic about prospects for Amylin’s GLP-1 franchise, and also hope to leverage their existing infrastructure as their fledgling diabetes franchise struggles to meet expectations.